Bryostatin 1 - CAS 83314-01-6
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Bryostatin 1, a structurally unique macrolactone marine natural product, is a protein kinase C (PKC) activator that binds with high affinity (Ki = 1.35 nM). Bryostatin 1 fails to mimic many effects caused by PMA and actually blocks some PMA-induced response in a variety of cells and tissues. Animal tests have shown bryostatin 1 may alleviate brain damage after a stroke.
Publictions citing BOC Sciences Products
  • >> More
White lyophilised solid
(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[,7.111,15]nonacos-8-en-12-yl-(2E, 4E)-2,4-octadienoic acid ester; Bryostatin 1; 83314-01-6; AC1L8WCW
Soluble in DMSO and in ethanol
Store at -20°C
Boiling Point:
954.7ºC at 760 mmHg
Canonical SMILES:
1.Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor.
Li H1,2, He H3, Gong L4, Fu M3, Wang TT2. AIDS Res Hum Retroviruses. 2016 Feb;32(2):174-7. doi: 10.1089/AID.2015.0343.
We report that the addition of an host paracaspase MALT1 inhibitor, MI-2, to HIV latently infected ACH-2, Jurkat E4, and J-LAT cells accelerated cell death in the presence of cell stimuli or the protein kinase C agonist, bryostatin 1. MI-2-mediated cell death correlated with the induction of the cellular RNase MCPIP1 and requires the presence of viral component(s). Altogether, the combination of MI-2 and bryostatin 1 displays selective killing of HIV latently infected CD4(+) T cells.
2.Isolation, analytical measurements, and cell line studies of the iron-bryostatin-1 complex.
Plummer S1, Manning T2, Baker T1, McGreggor T1, Patel M1, Wylie G3, Phillips D4. Bioorg Med Chem Lett. 2016 Mar 30. pii: S0960-894X(16)30333-X. doi: 10.1016/j.bmcl.2016.03.099. [Epub ahead of print]
Bryostatin-1 is a marine natural product that has demonstrated medicinal activity in pre-clinical and clinical trials for the treatment of cancer, Alzheimer's disease, effects of stroke, and HIV. In this study, iron-bryostatin-1 was obtained using a pharmaceutical aquaculture technique developed by our lab that cultivates marine bacteria for marine natural product extraction. Analytical measurements 1H and 13C NMR, mass spectrometry, and flame atomic absorption were utilized to confirm the presence of an iron-bryostatin-1 complex. The iron-bryostatin-1 complex produced was then tested against the National Cancer Institute's 60 cell line panel. Adding iron to bryostatin-1 lowered the anti-cancer efficacy of the compound.
3.Rescue of Synaptic Phenotypes and Spatial Memory in Young Fragile X Mice.
Sun MK1, Hongpaisan J2, Alkon DL2. J Pharmacol Exp Ther. 2016 May;357(2):300-10. doi: 10.1124/jpet.115.231100. Epub 2016 Mar 3.
Fragile X syndrome (FXS) is characterized by synaptic immaturity, cognitive impairment, and behavioral changes. The disorder is caused by transcriptional shutdown in neurons of thefragile X mental retardation 1gene product, fragile X mental retardation protein. Fragile X mental retardation protein is a repressor of dendritic mRNA translation and its silencing leads to dysregulation of synaptically driven protein synthesis and impairments of intellect, cognition, and behavior, and FXS is a disorder that currently has no effective therapeutics. Here, young fragile X mice were treated with chronic bryostatin-1, a relatively selective protein kinase Cεactivator, which induces synaptogenesis and synaptic maturation/repair. Chronic treatment with bryostatin-1 rescues young fragile X mice from the disorder phenotypes, including normalization of most FXS abnormalities in 1) hippocampal brain-derived neurotrophic factor expression, 2) postsynaptic density-95 levels, 3) transformation of immature dendritic spines to mature synapses, 4) densities of the presynaptic and postsynaptic membranes, and 5) spatial learning and memory.
4.Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy: a phase i, double-blind clinical trial.
Gutiérrez C1, Serrano-Villar S, Madrid-Elena N, Pérez-Elías MJ, Martín ME, Barbas C, Ruipérez J, Muñoz E, Muñoz-Fernández MA, Castor T, Moreno S. AIDS. 2016 Feb 17. [Epub ahead of print]
OBJECTIVE: The protein kinase C-(PKC) agonist bryostatin-1 has shown significant ex vivo potency to revert HIV-1 latency, compared to other latency reversing agents-(LRA). The safety of this candidate LRA remains to be proven in treated HIV-1 infected-patients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PKC Products

CAS 83314-01-6 Bryostatin 1

Bryostatin 1
(CAS: 83314-01-6)

Bryostatin 1, a structurally unique macrolactone marine natural product, is a protein kinase C (PKC) activator that binds with high affinity (Ki = 1.35 nM). Bry...

CAS 30220-46-3 Ingenol

(CAS: 30220-46-3)

Ingenol, the analogue of Ingenol 3-Angelate found in the seeds of Euphorbia lathyris L, is an extremely weak PKC (protein kinase C) activator ( Ki=30 μM, ED50=2...

CAS 193620-69-8 TAS-301

(CAS: 193620-69-8)

TAS-301 is a potent and selective constrictive remodeling regulator on renarrowing after balloon overstretch injury of porcine coronary artery. TAS-103 inhibits...

CAS 163751-35-7 rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate

(CAS: 163751-35-7)

The Pharmacological activity of this molecular is Growth Inhibition of Malignant Cells in vivo and in vitro and cytotoxic properties may result inhibition of pr...

CAS 87745-28-6 Bryostatin 2

Bryostatin 2
(CAS: 87745-28-6)

Bryostatin 2, an analog of Bryostatin 1, is an activator of PKC (protein kinase C) with anti-tumor properties. Bryostatin 2 inhibits DNA synthesis at 100 nM in ...

CAS 62996-74-1 Staurosporine

(CAS: 62996-74-1)

Staurosporine is broad spectrum protein kinase inhibitor. Enzymes inhibited include protein kinase C (IC50 = 3 nM), protein kinase A (IC50 = 7 nM), p60v-src tyr...

CAS 164658-13-3 CGP60474

(CAS: 164658-13-3)

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics rela...

CAS 60857-08-1 Prostratin

(CAS: 60857-08-1)

Prostratin is an activator of protein kinase C (PKC) and also an activator of nuclear factor KB (NF-KB) mediated through activation of the IKKs (IKB kinases). I...

CAS 17673-25-5 Phorbol

(CAS: 17673-25-5)

Phorbol, derived from the roots of Euphorbia pekinensis Rupr., as a tumor promoter it is able to activate protein kinase C.

CAS 425637-18-9 Sotrastaurin

(CAS: 425637-18-9)

Sotrastaurin, also known as AEB-701, is an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities....

CAS 37558-16-0 Phorbol 12,13-dibutyrate

Phorbol 12,13-dibutyrate
(CAS: 37558-16-0)

Phorbol 12,13-dibutyrate, a protein kinase C activator, stimulates the phosphorylation of Na+,K+- ATPase, thereby inhibiting its activity.

CAS 125314-64-9 RO31-8220

(CAS: 125314-64-9)

Ro 31-8220 is a PKC-inhibitor, which inhibits stimulated fluid pinocytosis of human PMNs induced by the PKC-activators phorbol myristate acetate or diacylglycer...

CAS 1874276-76-2 LXS196

(CAS: 1874276-76-2)

LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under clinical trials for the treatment of uveal melanoma, the most common cancer of the e...

CAS 3895-92-9 Chelerythrine Chloride

Chelerythrine Chloride
(CAS: 3895-92-9)

Chelerythrine is a cell-permeable inhibitor of protein kinase C (IC50 = 660 nM) with a wide range of biological activities.

CAS 120685-11-2 Midostaurin

(CAS: 120685-11-2)

Midostaurin is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

CAS 169939-93-9 Ruboxistaurin Hydrochloride

Ruboxistaurin Hydrochloride
(CAS: 169939-93-9)

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...

(CAS: 785718-37-8)

NSC305787 is a small molecule inhibitor of PKC. Its IC50 value is 8.3 μM, 9.4 μM, 55 μM for PKCΙ phosphorylation of recombinant ezrin, moesin and radixin. It is...

(CAS: 1046787-18-1)

PKC-IN-1 has been found to be a PKCβII inhibitor that probably has biological activity in antineoplastic studies. Ki: 14.9 nM.

CAS 138489-18-6 Ro 31-8220 Mesylate

Ro 31-8220 Mesylate
(CAS: 138489-18-6)

Ro 31-8220 inhibits rat brain PKC activity with IC50 of 23 nM, and does not show any high degree of selectivity between PKC-α, PKC-β, PKC-γ, and PKC-ε.

CAS 170364-57-5 Enzastaurin

(CAS: 170364-57-5)

Enzastaurin HCL is the hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity. Binding to the ATP-...

Chemical Structure

CAS 83314-01-6 Bryostatin 1

Quick Inquiry

Verification code

Featured Items